Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$9.39	$8.11	$6.38 ▼ $17.51	$907.35M	1.4	1.23 million shs	1.36 million shs
ELVN Enliven Therapeutics	$18.51 -0.6%	$19.06	$13.30 ▼ $30.03	$908.21M	1.07	259,905 shs	511,962 shs
MLYS Mineralys Therapeutics	$14.65 -6.1%	$13.98	$8.24 ▼ $18.38	$950.43M	-0.3	447,023 shs	644,840 shs
PVLA Palvella Therapeutics	$22.77 -1.2%	$24.90	$6.20 ▼ $29.27	$251.45M	0.1	70,043 shs	17,462 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	-0.79%	+9.06%	+42.49%	+15.78%	-42.22%
ELVN Enliven Therapeutics	+1.90%	-6.15%	+17.76%	-15.32%	-23.93%
MLYS Mineralys Therapeutics	+6.23%	+4.34%	+32.63%	+59.12%	+6.55%
PVLA Palvella Therapeutics	+4.63%	-4.36%	+12.34%	+48.17%	+2,303,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	2.4357 of 5 stars	3.5	2.0	3.2	1.7	0.6
ELVN Enliven Therapeutics	2.0397 of 5 stars	3.6	0.0	2.1	4.2	0.0
MLYS Mineralys Therapeutics	2.3478 of 5 stars	3.5	1.0	1.8	5.0	0.0
PVLA Palvella Therapeutics	3.6205 of 5 stars	4.6	0.0	3.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$19.43	106.91% Upside
ELVN Enliven Therapeutics	3.25	Buy	$40.33	117.90% Upside
MLYS Mineralys Therapeutics	3.00	Buy	$33.00	125.26% Upside
PVLA Palvella Therapeutics	3.13	Buy	$44.43	95.12% Upside

Current Analyst Ratings Breakdown

Latest PVLA, MLYS, AVDL, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/9/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/9/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
4/2/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00 ➝ $42.00
4/1/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
3/26/2025	PVLA Palvella Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$45.00
3/25/2025	PVLA Palvella Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$45.00
3/24/2025	PVLA Palvella Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/21/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $39.00
3/10/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	5.37	N/A	N/A	$0.98 per share	9.58
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$5.97 per share	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
PVLA Palvella Therapeutics	$42.81M	5.87	N/A	N/A	$21.66 per share	1.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$160.28M	-$0.52	N/A	156.50	N/A	-52.53%	-93.34%	-44.77%	N/A
ELVN Enliven Therapeutics	-$71.58M	-$1.89	N/A	N/A	N/A	N/A	-29.46%	-27.33%	5/13/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.64	N/A	N/A	N/A	N/A	-67.97%	-62.40%	5/12/2025 (Estimated)
PVLA Palvella Therapeutics	-$24.54M	-$12.10	N/A	N/A	N/A	N/A	-80.93%	-59.55%	5/15/2025 (Estimated)

Latest PVLA, MLYS, AVDL, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
3/13/2025	Q4 2024	ELVN Enliven Therapeutics	-$0.53	-$0.46	+$0.07	-$0.46	N/A	$0.03 million
2/12/2025	Q4 2024	MLYS Mineralys Therapeutics	-$1.00	-$0.98	+$0.02	-$0.98	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.97	2.60
ELVN Enliven Therapeutics	N/A	17.44	17.44
MLYS Mineralys Therapeutics	N/A	14.02	14.02
PVLA Palvella Therapeutics	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
ELVN Enliven Therapeutics	95.08%
MLYS Mineralys Therapeutics	84.46%
PVLA Palvella Therapeutics	40.11%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	4.80%
ELVN Enliven Therapeutics	29.20%
MLYS Mineralys Therapeutics	25.56%
PVLA Palvella Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.63 million	91.74 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	34.59 million	Optionable
MLYS Mineralys Therapeutics	28	64.88 million	33.27 million	Optionable
PVLA Palvella Therapeutics	N/A	11.04 million	10.50 million	N/A

PVLA, MLYS, AVDL, and ELVN Headlines

Recent News About These Companies

Palvella Therapeutics to Ring Nasdaq Opening Bell

May 9 at 6:32 PM | msn.com

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

May 8 at 7:30 AM | globenewswire.com

Renaissance Technologies LLC Buys New Holdings in Palvella Therapeutics (NASDAQ:PVLA)

May 8 at 3:15 AM | marketbeat.com

BVF Inc. IL Purchases New Stake in Palvella Therapeutics (NASDAQ:PVLA)

May 6 at 7:31 AM | marketbeat.com

Geode Capital Management LLC Invests $171,000 in Palvella Therapeutics (NASDAQ:PVLA)

May 6 at 3:06 AM | marketbeat.com

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

May 5, 2025 | globenewswire.com

Adams Street Partners LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)

May 4, 2025 | marketbeat.com

HC Wainwright Reiterates Buy Rating for Palvella Therapeutics (NASDAQ:PVLA)

May 2, 2025 | marketbeat.com

Samsara BioCapital LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)

May 2, 2025 | marketbeat.com

Nantahala Capital Management LLC Buys Shares of 250,062 Palvella Therapeutics (NASDAQ:PVLA)

April 30, 2025 | marketbeat.com

Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025

April 30, 2025 | insidermonkey.com

Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Down 8.38%

April 29, 2025 | aaii.com

Palvella Therapeutics to Present Key Findings on Lymphatic Malformations at Dermatology Conference

April 28, 2025 | msn.com

One Palvella Therapeutics Insider Raised Their Stake In The Previous Year

April 26, 2025 | finance.yahoo.com

Blue Owl Capital Holdings LP Takes $3 Million Position in Palvella Therapeutics (NASDAQ:PVLA)

April 26, 2025 | marketbeat.com

Palvella Therapeutics secures new patent for rare skin disease gel

April 24, 2025 | uk.investing.com

Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin

April 23, 2025 | msn.com

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

April 23, 2025 | globenewswire.com

Palvella Therapeutics Secures Fifth U.S. Patent for QTORIN™ Rapamycin, Advancing Treatment for Microcystic Lymphatic Malformations

April 22, 2025 | quiverquant.com

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

April 22, 2025 | globenewswire.com

Palvella Therapeutics (NASDAQ:PVLA) Given Average Recommendation of "Buy" by Analysts

April 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, MLYS, AVDL, and ELVN Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$9.39 0.00 (0.00%)

As of 04:00 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Enliven Therapeutics NASDAQ:ELVN

$18.51 -0.12 (-0.64%)

As of 03:52 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Mineralys Therapeutics NASDAQ:MLYS

$14.65 -0.96 (-6.15%)

As of 04:00 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Palvella Therapeutics NASDAQ:PVLA

$22.77 -0.27 (-1.17%)

As of 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time